Parmax Pharma Ltd
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of Employees count ・Standalone data |
|
||||||||
| Domestic (Local) Sales Share in Revenue from Operations % ・Standalone data |
|||||||||
| Export Sales Share in Revenue from Operations % ・Standalone data |
|||||||||
| Labour Job Work Share in Revenue from Operations % ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- Parmax Pharma held its 32nd AGM on 29 September 2026; shareholders approved financials and director appointments.
- Closure of Trading Window
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 - Intimation Of Fire Incident At The Plant Of The Company
- Major fire at Parmax Pharma's Rajkot plant on September 28, 2026; two employees injured, damage being assessed.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication for 32nd Annual general Meeting of the Company
-
Reg. 34 (1) Annual Report.
- FY26 annual report filed; 32nd AGM on Sept 29, 2026 via VC/OAVM with e-voting schedule.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
Business Overview:[1]
PPL is engaged in the manufacture and supply
of bulk drugs (APIs) and selected formulations
catering primarily to the Indian pharma industry.